Product Description
Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues. It is well absorbed and effective in suppressing isolated premature ventricular contractions (PVCs) or nonsustained ventricular arrhythmia but has only a modest efficacy when electrophysiologic testing is used as an endpoint (Sourced from: https://pubmed.ncbi.nlm.nih.gov/7889236/)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: InCarda Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Greece, Norway
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Atrial Fibrillation|Cardiac Arrest|Cardiac Arrhythmias|Coronary Artery Disease|Mitral Valve Prolapse|Myocardial Ischemia